Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction

Recent studies have demonstrated that histopathologic features of inherited breast cancers due to BRCA1 gene mutations often differ from those of sporadic breast cancer and from breast cancers caused by germline BRCA2 mutations. Invasive breast carcinomas in individuals with germline BRCA1 gene mutations tend to be of higher grade, either basal-type or basal-like, estrogen receptor (ER) negative, progesterone receptor (PR) negative, HER2-Neu (ERBB-2) negative, cytokeratin 5/6 (CK5/6) positive, CK14 positive. Incorporating this information into our Mendelian risk prediction model, BRCAPRO may allow for improved estimation of BRCA1 and BRCA2 carrier risk.

• Publication year

  2008

• Venue

  Breast Cancer Research

• Publication date

  2008-03-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/bcr1866PMID 18466632PMCID 2397515
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Applications in Genetics and Molecular Biology BayesMendel : an R Environment for Mendelian Risk Prediction

  2011cited by this paper
• Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.

  2006cited by this paper
• Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

  2005influential reference
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

  1998cited by this paper

• A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO

  2021cites this paper
• Simpson's paradox in the integrated discrimination improvement

  2017cites this paper
• Adaptation of the Genetic Risk Prediction Model BRCAPRO for Primary Care Settings

  2017influential citation
• A two-stage approach to genetic risk assessment in primary care

  2016cites this paper
• KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients

  2016cites this paper
• Fiatalkorban előforduló emlőcarcinomák patológiai és molekuláris patológiai sajátosságai és ezek összefüggése a prognózissal

  2016cites this paper
• Evaluating Changes in Patient Anxiety Regarding Classic Cancer Genetic Testing Versus Expanded Multiplex Cancer Genetic Testing

  2015cites this paper
• Recent BRCAPRO upgrades significantly improve calibration

  2014cites this paper
• Recent BRCAPRO Upgrades Significantly Improve Calibration

  2014cites this paper
• Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

  2014cites this paper
• Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.

  2014cites this paper
• Reclassification of predictions for uncovering subgroup specific improvement

  2014cites this paper
• Providing access to risk prediction tools via the HL7 XML-formatted risk web service

  2013cites this paper
• Identifying Women at High Risk of Breast Cancer: Understanding the Risk Models

  2013cites this paper
• Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

  2013cites this paper
• BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface

  2013cites this paper
• Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

  2013cites this paper
• Simplifying clinical use of the genetic risk prediction model BRCAPRO

  2013cites this paper
• Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

  2012cites this paper
• Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO

  2012cites this paper
• Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA )

  2011cites this paper
• Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

  2011cites this paper
• BRCA1/2 mutations and triple negative breast cancers.

  2010cites this paper
• Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers

  2009cites this paper
• Absence of germline BRCA1 mutations in familial pancreatic cancer patients

  2009cites this paper